选择立即根治性前列腺切除术男性的不良病理发现:定义有利中危组
这项回顾性队列研究纳入2005年至2016年7月在约翰霍普金斯医院接受根治性前列腺切除术的极低危、低危和低容量中危前列腺癌患者,比较不良病理发现率。低容量中危组不良病理发现率显著高于低危和极低危组,且无术前标准能识别出与极低危/低危相当的不良病理亚组。
要点
- 低容量中危患者不良病理发现率为24.7%(150/608),显著高于低危的5.8%和极低危的4.7%。
- 将低容量中危患者限制于额外标准并未显著影响结果。
- 无术前临床或病理标准能识别出不良病理发现率与极低危和低危队列相当的亚组。
核心结论
- 近25%的低容量Gleason 3+4=7前列腺癌患者在选择立即根治性前列腺切除术后发现不良手术病理结果。
- 这些数据不支持纳入患者中存在「有利」亚组,可能对类似Gleason 3+4=7前列腺癌患者的主动监测有重要意义。
研究设计与样本
- 回顾性队列研究,纳入2005年至2016年7月在约翰霍普金斯医院接受根治性前列腺切除术的临床局限性前列腺癌男性。
- 极低危组1264例,低危组4849例,低容量中危组608例(1-2针阳性,Gleason 3+4=7,前列腺特异性抗原[PSA]水平<20 ng/mL)。
- 采用对数二项回归计算低容量中危队列相较于极低危和低危队列的不良病理发现相对风险(RR)。
- 在低容量中危人群中,对符合极低危标准(T1c,PSA密度[PSAD]<0.15 ng/mL/cm3,任一针穿刺癌组织≤50%)和低危标准(≤T2a,PSA水平<10 ng/mL)的亚组重复分析。
- 基于各种临床阈值计算低容量中危组内不良病理发现率,并进行单变量和多变量逻辑回归分析以识别不良病理发现的预测因素。
主要发现
- 低容量中危组不良病理发现率为24.7%(150/608),显著高于低危组的5.8%(280/4849),RR为4.50(95% CI 3.73-5.43,P<.001)。
- 低容量中危组不良病理发现率显著高于极低危组的4.7%(60/1264),RR为5.14(95% CI 3.84-6.89,P<.001)。
- 将低容量中危患者限制于额外标准并未显著影响结果。
- 无术前临床或病理标准能识别出低容量中危人群中不良病理发现率与极低危和低危队列相当的亚组。
- PSAD是不良病理发现的显著预测因素,但Gleason评分效应最大(比值比4.30,95% CI 3.40-5.44,P<.001)。
关键数值与推荐
- 低容量中危定义为1-2针阳性、Gleason 3+4=7、PSA<20 ng/mL。
- 极低危额外标准:T1c、PSAD<0.15 ng/mL/cm3、任一针穿刺癌组织≤50%。
- 低危额外标准:≤T2a、PSA<10 ng/mL。
- 不良病理发现定义为至少Gleason 4+3=7疾病及其他不良病理特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Active surveillance is recommended for patients with very low-risk (VLR) and low-risk (LR) prostate cancer. Despite controversy, recent clinical guidelines state surveillance may be considered for men with low-volume intermediate-risk (LVIR) disease. OBJECTIVE: To compare rates of adverse pathologic findings among VLR, LR, and LVIR men electing immediate radical prostatectomy and evaluate criteria to define if a favorable intermediate-risk group minimizing risk exists. DESIGN, SETTING, AND PARTICIPANTS: This was a cohort study of men (2005-July 2016) with clinically localized VLR (1264 patients), LR (4849 patients), and LVIR (608 patients) (1-2 cores, Gleason 3 + 4 = 7, prostate-specific antigen [PSA] level <20 ng/mL) prostate cancer undergoing radical prostatectomy evaluated retrospectively at Johns Hopkins Hospital. INTERVENTIONS: Radical prostatectomy. MAIN OUTCOMES AND MEASURES: The proportions of men found to have at least Gleason 4 + 3 = 7 disease and other adverse pathologic features were compared by risk group. Log-binomial regression calculated relative risk (RR) of adverse pathologic findings in the LVIR cohort compared with VLR and LR cohorts. Analyses were repeated in subgroups of the LVIR population who otherwise met criteria for VLR (T1c, PSA density [PSAD] <0.15 ng/mL/cm3, ≤50% cancer in any core) and LR (≤T2a, PSA level <10 ng/mL) disease. Rates of adverse pathologic findings within the LVIR group were calculated based on various clinical thresholds, and univariable and multivariable logistic regression analyses were performed to identify predictors of adverse pathologic findings. RESULTS: The rate of adverse pathologic findings was significantly higher for LVIR disease (150 of 608 patients [24.7%]; RR, 4.50; 95% CI, 3.73-5.43; P < .001) compared with LR disease (280 of 4849 [5.8%]), and LVIR disease (RR, 5.14; 95% CI, 3.84-6.89; P < .001) compared with men with VLR disease (60 of 1264 [4.7%]). Restriction of LVIR men to additional criteria did not significantly affect results. There were no preoperative clinical or pathologic criteria that could identify a subgroup of the LVIR population with rates of adverse pathologic findings comparable with those of the VLR and LR cohorts. PSAD was a significant predictor of adverse pathologic findings, but Gleason score had the largest effect (odds ratio, 4.30 (95% CI, 3.40-5.44; P < .001). CONCLUSIONS AND RELEVANCE: Nearly 25% of men (150 of 608) electing immediate radical prostatectomy with low-volume, Gleason 3 + 4 prostate cancer on biopsy are found to harbor adverse surgical pathologic findings. These data do not support the presence of a "favorable" subgroup among included patients and could have important implications for active surveillance in similar patients with Gleason 3 + 4 = 7 prostate cancer.
引用
- Patel HD, Tosoian JJ, Carter HB, et al. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group. JAMA Oncol. 2018. PMID: 28715578. doi:10.1001/jamaoncol.2017.1879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。